Terms: = Ovarian cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
55 results:
1. Inter observer reliability for peritoneal carcinomatosis at computed tomography.
Hafeez M; Sattar A; Farooqui WA
J Pak Med Assoc; 2023 May; 73(5):973-977. PubMed ID: 37218220
[TBL] [Abstract] [Full Text] [Related]
2. HAX1-related congenital neutropenia: Long-term observation in paediatric and adult patients enrolled in the European branch of the Severe Chronic Neutropenia International Registry (SCNIR).
Pogozhykh D; Yilmaz Karapinar D; Klimiankou M; Gerschmann N; Ebetsberger-Dachs G; Palmblad J; Carlsson G; Masmas T; Kinsey S; Bartels M; Mellor-Heineke S; Welte K; Skokowa J; Zeidler C
Br J Haematol; 2023 Jul; 202(2):393-411. PubMed ID: 37193639
[TBL] [Abstract] [Full Text] [Related]
3. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous ovarian cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract] [Full Text] [Related]
4. NCOA1/2/3 rearrangements in uterine tumor resembling ovarian sex cord tumor: A clinicopathological and molecular study of 18 cases.
Lu B; Xia Y; Chen J; Tang J; Shao Y; Yu W
Hum Pathol; 2023 May; 135():65-75. PubMed ID: 36646185
[TBL] [Abstract] [Full Text] [Related]
5. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G
Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207
[TBL] [Abstract] [Full Text] [Related]
6. Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in ovarian cancer Cells.
Ovejero-Sánchez M; Asensio-Juárez G; González M; Puebla P; Vicente-Manzanares M; Pélaez R; González-Sarmiento R; Herrero AB
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361809
[TBL] [Abstract] [Full Text] [Related]
7. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract] [Full Text] [Related]
8. An update on the safety of olaparib for treating ovarian cancer.
Cottrell K; Clark CL; Penson RT
Expert Opin Drug Saf; 2022 Apr; 21(4):447-451. PubMed ID: 35212587
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E
Gynecol Oncol; 2022 Apr; 165(1):40-48. PubMed ID: 35115180
[TBL] [Abstract] [Full Text] [Related]
10. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian cancer.
Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
[TBL] [Abstract] [Full Text] [Related]
11. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
Morra A; Escala-Garcia M; Beesley J; Keeman R; Canisius S; Ahearn TU; Andrulis IL; Anton-Culver H; Arndt V; Auer PL; Augustinsson A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brenner H; Brüning T; Buys SS; Caan B; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Cheng TD; Clarke CL; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Dörk T; Dossus L; Dunning AM; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; Gago-Dominguez M; García-Sáenz JA; Giles GG; Grip M; Guénel P; Gündert M; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Hart SN; Hartikainen JM; Hartmann A; He W; Hooning MJ; Hoppe R; Hopper JL; Howell A; Hunter DJ; ; ; Jager A; Jakubowska A; Janni W; John EM; Jung AY; Kaaks R; Keupers M; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kurian AW; Lacey JV; Lambrechts D; Le Marchand L; Lindblom A; Linet M; Luben RN; Lubiński J; Lush M; Mannermaa A; Manoochehri M; Margolin S; Martens JWM; Martinez ME; Mavroudis D; Michailidou K; Milne RL; Mulligan AM; Muranen TA; Nevanlinna H; Newman WG; Nielsen SF; Nordestgaard BG; Olshan AF; Olsson H; Orr N; Park-Simon TW; Patel AV; Peissel B; Peterlongo P; Plaseska-Karanfilska D; Prajzendanc K; Prentice R; Presneau N; Rack B; Rennert G; Rennert HS; Rhenius V; Romero A; Roylance R; Ruebner M; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Smichkoska S; Southey MC; Stone J; Surowy H; Swerdlow AJ; Tamimi RM; Tapper WJ; Teras LR; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Truong T; Vachon CM; Wang Q; Hurson AN; Winqvist R; Wolk A; Ziogas A; Brauch H; García-Closas M; Pharoah PDP; Easton DF; Chenevix-Trench G; Schmidt MK
Breast Cancer Res; 2021 Aug; 23(1):86. PubMed ID: 34407845
[TBL] [Abstract] [Full Text] [Related]
12. QSCR Analysis of Cytotoxicity of 6-Fluoro-3-(4H-1,2,4-triazol-3- yl)quinolin-4(1H)-ones on Chinese Hamster Ovary Cell Line: Design of REPUBLIC1986.
Joon S; Singla RK; Shen B; Kamal MA
Curr Med Chem; 2022; 29(2):369-379. PubMed ID: 34165404
[TBL] [Abstract] [Full Text] [Related]
13. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
[TBL] [Abstract] [Full Text] [Related]
14. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
[TBL] [Abstract] [Full Text] [Related]
15. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract] [Full Text] [Related]
16. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications.
Kommoss FK; Chang KT; Stichel D; Banito A; Jones DT; Heilig CE; Fröhling S; Sahm F; Stenzinger A; Hartmann W; Mechtersheimer G; Sinn HP; Schmidt D; Kommoss F; von Deimling A; Koelsche C
J Pathol Clin Res; 2020 Jul; 6(3):178-184. PubMed ID: 32352245
[TBL] [Abstract] [Full Text] [Related]
17. Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.
Rauh LA; Sullivan MW; Camacho F; Janke MJ; Duska LR; Chandler C; Sukumvanich P; Courtney-Brooks M; Lefkowits C
Gynecol Oncol; 2020 Jun; 157(3):754-758. PubMed ID: 32171568
[TBL] [Abstract] [Full Text] [Related]
18. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract] [Full Text] [Related]
19. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics.
Kommoss FKF; Stichel D; Schrimpf D; Kriegsmann M; Tessier-Cloutier B; Talhouk A; McAlpine JN; Chang KTE; Sturm D; Pfister SM; Romero-Pérez L; Kirchner T; Grünewald TGP; Buslei R; Sinn HP; Mechtersheimer G; Schirmacher P; Schmidt D; Lehr HA; Sahm F; Huntsman DG; Gilks CB; Kommoss F; von Deimling A; Koelsche C
J Cancer Res Clin Oncol; 2020 Jan; 146(1):97-104. PubMed ID: 31768620
[TBL] [Abstract] [Full Text] [Related]
20. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
O'Cearbhaill RE; Deng W; Chen LM; Lucci JA; Behbakht K; Spirtos NM; Muller CY; Benigno BB; Powell MA; Berry E; Tewari KS; Hanjani P; Lankes HA; Aghajanian C; Sabbatini PJ
Gynecol Oncol; 2019 Dec; 155(3):393-399. PubMed ID: 31653510
[TBL] [Abstract] [Full Text] [Related]
[Next]
